PDA Technical Report No. 73 (TR 73) Prefilled Syringe User Requirements for Biotechnology Applications (single user digital version)

Published
Oct 2015
ISBN
9780939459827
Pages
117
PDA Item Number
43525

Premium Members: to claim your annual free technical document download, email membership@pda.org and indicate the document you wish to claim.

Format
PDF Single user
Member Price
$180.00
Nonmember Price
$325.00
Government Price
$180.00

PDA Technical Report No. 73 (TR 73) Prefilled Syringe User Requirements for Biotechnology Applications discusses the requirements for the 1 mL long glass prefilled syringe (PFS) for biotechnology applications.

Over the past decade, a large number of subcutaneously injected biotechnology drug products have been packaged in PFSs because of the benefits compared to vials or ampules. The benefits of PFSs include reduction of medical dosing errors, reduction in risk of microbial contamination by decreased manipulation prior to injection, and improved compliance due to ease of use. In addition to the patient benefits, PFSs often have lower overfill regulatory requirements than vials, thereby reducing product waste.

This report provides guidance on material selection and evaluation for suitability, syringe preparation and handling (including human factors), and drug product compatibility (physical and chemical) with the syringe materials and mode of delivery. Plastic syringes and ancillary devices, such as autoinjectors, are not within scope.

Available to download. Prior to purchase please view the download instructions and Terms of Usage.
Format: PDF (1 file 3.11 MB)

Click here to order paper ship version (Item no. 01073).

*To purchase licensing, please contact PDA at info@pda.org.

Table of Contents

Table of Contents:

Click here to download >>> Detailed Table of Contents
  1. Introduction
  2. Glossary of Terms
  3. Prefilled Syringe Development and Licensing
  4. PFS Human Factors Engineering
  5. Extractables and Leachables Evaluation
  6. Glass Barrel Requirements
  7. Needle Requirements
  8. Needle-Shield Requirements
  9. Cosmetic Imperfections
  10. Siliconization
  11. Plunger Stopper Suitability
  12. Container Closure Integrity Requirements
  13. Manufacturing Requirements
  14. Drug Product Compatibility
  15. Appendix I: Electronic Common Technical Document (ECTD) Application Submission Overview
  16. Appendix II: Module 3 For Electronic Common Technical Document (ECTD) Submission Overview
  17. Appendix III: Tests, Standards, and Guidance Documents for PFS Combination Products
  18. Appendix IV: Compound Classification with the Associated Threshold of Toxicological Concern (TTC)
  19. References

Figures and Tables Index

About the Authors

Ron Forster, Ph.D., Amgen, Team Leader

Ross Allen, Eli Lilly and Company

Khandan Baradaran, Dimension Therapeutics

Sherri Biondi, Genentech

Alfred Breunig, Nipro Glass Germany AG

Charlene Brisbane, GlaxoSmithKline

Anil Busimi, Schott

Rey Chern, Ph.D., Amgen

Piet Christiaens, Ph.D., Toxikon Europe NV

Jean-François DeCoster, UCB Pharma S.A.

Andrew Donnelly, Bespak

Peter Gassmann, Ph.D., Johnson & Johnson

Aarti Gidh, Ph.D., GlaxoSmithKline

Heike Gruen, West Pharmaceutical Services

Olivia Henderson, Ph.D., Biogen

Carl Hitscherich, Ph.D., Biogen

Tibor Hlobik, West Pharmaceutical Services

Colleen Hutter, Merck

Renaud Janssen, Datwyler Pharma Packaging Belgium NV

Laurent Jeanmart, Ph.D., GlaxoSmithKline Biologicals

Akshay Kamdar, Ph.D., Eli Lilly and Company

Suzanne Kiani, Amgen

James Kershner, Eli Lilly and Company

Lei Li, Ph.D., Eli Lilly and Company

Alice Maden, Becton Dickinson

Mary Mathieu, AbbVie

Kingman Ng, Ph.D., Novartis

QuynhNhu Nguyen, FDA/CDRH

Thomas Nikolai, Hospira

Carlos Ortiz, Eli Lilly and Company

Bruno Reuter, Nipro Europe NV

Julio Rivera, SiO2 Medical Products

Lesbeth C. Rodriguez, Bayer Healthcare Pharmaceuticals, Inc

Andrea Salmaso, Pharma.D., Stevanato Group spa

Thomas Schönknecht, SHL

Jörg Sielemann, F. Hoffmann La Roche AG

Hervé Soukiassian, Becton Dickinson

Kalavati Suvarna, Ph.D., FDA

Robert Swift, Ompi

Randy Thackrey, Eli Lilly and Company

Raja Thyagarajapuram, Ph.D., Eli Lilly and Company

Simon Toth, Dow Corning Corporation

Li-Chun Tsou, Ph.D., AstraZeneca

Tina Tubbs, Sanofi-Pasteur

Paulo Villaneuva, Genentech

Lee Wood, F. Hoffmann La Roche AG

Jörg Zimmermann, Vetter Pharma

Daniele Zuccato, Stevanato Group spa